Published in Int J Radiat Oncol Biol Phys on October 23, 2010
External beam accelerated partial-breast irradiation using 32 gy in 8 twice-daily fractions: 5-year results of a prospective study. Int J Radiat Oncol Biol Phys (2012) 0.89
Four-year clinical update from a prospective trial of accelerated partial breast intensity-modulated radiotherapy (APBIMRT). Breast Cancer Res Treat (2013) 0.84
Investigation of variability in image acquisition and contouring during 3D ultrasound guidance for partial breast irradiation. Radiat Oncol (2014) 0.80
Toxicity and cosmesis outcomes after single fraction partial breast irradiation in early stage breast cancer. Radiat Oncol (2011) 0.78
Estimated effects of potential interventions to prevent decreases in self-rated health among breast cancer survivors. Ann Epidemiol (2012) 0.77
A novel schedule of accelerated partial breast radiation using intensity-modulated radiation therapy in elderly patients: survival and toxicity analysis of a prospective clinical trial. Radiat Oncol J (2017) 0.75
Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ (2006) 9.04
Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol (2006) 6.24
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol (2010) 5.44
A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol (2008) 5.26
Potassium permanganate reaction in amyloidosis. A histologic method to assist in differentiating forms of this disease. Lab Invest (1977) 4.21
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86
Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology (2008) 3.71
Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol (2011) 3.05
Assessing the quality of decision support technologies using the International Patient Decision Aid Standards instrument (IPDASi). PLoS One (2009) 2.97
Sec6/8 complexes on trans-Golgi network and plasma membrane regulate late stages of exocytosis in mammalian cells. J Cell Biol (2001) 2.69
Surfactant proteins a and d and pulmonary host defense. Annu Rev Physiol (2001) 2.61
Treatment decision aids: conceptual issues and future directions. Health Expect (2005) 2.25
Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med (1999) 2.20
Surfactant protein D stimulates phagocytosis of Pseudomonas aeruginosa by alveolar macrophages. Am J Respir Cell Mol Biol (1999) 2.04
Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.00
Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol (2013) 1.99
Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure. Oral Oncol (2012) 1.98
Shared treatment decision making: what does it mean to physicians? J Clin Oncol (2003) 1.97
The importance of reporting patient recruitment details in phase III trials. J Clin Oncol (2006) 1.92
Salivary agglutinin, which binds Streptococcus mutans and Helicobacter pylori, is the lung scavenger receptor cysteine-rich protein gp-340. J Biol Chem (2000) 1.89
Surfactant apoprotein Mr = 26,000-36,000 enhances uptake of liposomes by type II cells. J Biol Chem (1987) 1.88
Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol (2013) 1.81
Pulmonary surfactant and its components inhibit secretion of phosphatidylcholine from cultured rat alveolar type II cells. Proc Natl Acad Sci U S A (1987) 1.79
Relationship of amyloid to aging. Review of the literature and systematic study of 83 patients derived rom a general hospital population. Medicine (Baltimore) (1969) 1.79
Surfactant protein D enhances bacterial antigen presentation by bone marrow-derived dendritic cells. Am J Physiol Lung Cell Mol Physiol (2001) 1.78
Normal serum ferritin concentrations in precirrhotic hemochromatosis. N Engl J Med (1976) 1.68
Self-reported use of shared decision-making among breast cancer specialists and perceived barriers and facilitators to implementing this approach. Health Expect (2004) 1.67
Human pulmonary surfactant protein (SP-A), a protein structurally homologous to C1q, can enhance FcR- and CR1-mediated phagocytosis. J Biol Chem (1989) 1.64
Is mastectomy superior to breast-conserving treatment for young women? Int J Radiat Oncol Biol Phys (2007) 1.58
Aspergillosis in four renal transplant recipients. Diagnosis and effective treatment with amphotericin B. Ann Intern Med (1972) 1.58
Metabolism and turnover of lung surfactant. Am Rev Respir Dis (1987) 1.56
Reducing patient wait times and improving resource utilization at British Columbia Cancer Agency's ambulatory care unit through simulation. Health Care Manag Sci (2009) 1.54
Clinical-pathologic differentiation of common amyloid syndromes. Medicine (Baltimore) (1981) 1.53
Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era. Radiat Oncol (2011) 1.51
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ (2004) 1.51
Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-ST2 breast cancer. Int J Radiat Oncol Biol Phys (2002) 1.50
Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol (2008) 1.49
Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. Radiother Oncol (2002) 1.49
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol (2009) 1.48
Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer (2010) 1.47
Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer (2005) 1.47
Postmastectomy radiation therapy after immediate two-stage tissue expander/implant breast reconstruction: a University of British Columbia perspective. Plast Reconstr Surg (2014) 1.47
Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo. Am J Physiol Lung Cell Mol Physiol (2000) 1.45
Acute renal failure in multiple myeloma. Medicine (Baltimore) (1975) 1.43
Recombinant rat surfactant-associated protein D inhibits human T lymphocyte proliferation and IL-2 production. J Immunol (1998) 1.42
Identification and characterization of human surfactant protein A binding protein of Mycoplasma pneumoniae. Infect Immun (2005) 1.41
The association of the palliative performance scale and hazard of death in an ambulatory cancer population. J Palliat Med (2012) 1.41
Subfractionation of lung surfactant. Implications for metabolism and surface activity. Biochim Biophys Acta (1983) 1.40
Expression of C-reactive protein by alveolar macrophages. J Immunol (1996) 1.38
Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol (2012) 1.38
A systematic review of studies evaluating diffusion and dissemination of selected cancer control interventions. Health Psychol (2005) 1.36
Surfactant protein A enhances alveolar macrophage phagocytosis of apoptotic neutrophils. J Immunol (2001) 1.34
Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for 1-3 brain metastases: a feasibility study using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys (2009) 1.30
Clinician-patient communication: a systematic review. Support Care Cancer (2009) 1.27
Fluorocarbohydrates. XXIV. Chemical and enzymic reduction and phosphorylation of 6-deoxy-6-fluoro- -D-galactose. Carbohydr Res (1972) 1.26
Cultural influences on the physician-patient encounter: The case of shared treatment decision-making. Patient Educ Couns (2006) 1.26
Surfactant protein-A binds group B streptococcus enhancing phagocytosis and clearance from lungs of surfactant protein-A-deficient mice. Am J Respir Cell Mol Biol (1999) 1.24
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol (2010) 1.23
Glycoprotein-340 binds surfactant protein-A (SP-A) and stimulates alveolar macrophage migration in an SP-A-independent manner. Am J Respir Cell Mol Biol (1999) 1.22
Cytosolic factors which affect microsomal lipid peroxidation in lung and liver. Arch Biochem Biophys (1981) 1.22
Renal function in patients with multiple myeloma. Medicine (Baltimore) (1978) 1.22
Electron spin resonance studies of free radicals derived from plastoquinone, alpha- and gamma-tocopherol and their relation to free radicals observed in photosynthetic materials. Biochim Biophys Acta (1969) 1.21
Surfactant protein A stimulates phagocytosis of specific pulmonary pathogens by alveolar macrophages. Am J Physiol (1996) 1.20
Complement-mediated host defense in the lung. Am J Physiol Lung Cell Mol Physiol (2000) 1.20
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2011) 1.20
Amyloid in the aged heart: frequency and clinical significance. J Am Geriatr Soc (1975) 1.20
Synthesis and antibacterial activities of 1-N [(S)-omega-amino-2-hydroxyalkyl] kanamycin A derivatives. J Antibiot (Tokyo) (1977) 1.17
Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system. Int J Radiat Oncol Biol Phys (2007) 1.17
A systematic review of information in decision aids. Health Expect (2007) 1.16
Surfactant protein A enhances alveolar macrophage phagocytosis of a live, mucoid strain of P. aeruginosa. Am J Physiol (1999) 1.16
Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys (2003) 1.15
Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras. Radiat Oncol (2013) 1.14
Protein composition of rabbit alveolar surfactant subfractions. Biochim Biophys Acta (1984) 1.14
A Phase I-II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.14
A population-based study of the fractionation of postlumpectomy breast radiation therapy. In regard to Ashworth et al. Int J Radiat Oncol Biol Phys (2013) 1.13
Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol (2012) 1.12
Surfactant proteins A and D increase in response to intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol (1996) 1.12
Clinical experience using hypofractionated radiation schedules in breast cancer. Semin Radiat Oncol (2008) 1.11
Surfactant protein a promotes attachment of Mycobacterium tuberculosis to alveolar macrophages during infection with human immunodeficiency virus. Proc Natl Acad Sci U S A (1995) 1.10
In vivo vital staining as an aid to identification of esophagogastric mucosal junction in man. Am J Dig Dis (1972) 1.10
Hepatoprotective and free radical scavenging activities of phenolic petrosins and flavonoids isolated from Equisetum arvense. J Ethnopharmacol (2004) 1.10
Influence of age and previous use of diazepam dosage required for endoscopy. Can Med Assoc J (1978) 1.09
Gender differences in colorectal cancer incidence, mortality, hospitalizations and surgical procedures in Canada. J Public Health (Oxf) (2008) 1.09
Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. Int J Radiat Oncol Biol Phys (2010) 1.09
Surfactant protein A protects growing cells and reduces TNF-alpha activity from LPS-stimulated macrophages. Am J Physiol (1996) 1.08
Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy. J Clin Oncol (2008) 1.08
Antinociceptive mechanisms of orally administered decursinol in the mouse. Life Sci (2003) 1.08
Surfactant protein A (SP-A) mediates attachment of Mycobacterium tuberculosis to murine alveolar macrophages. Am J Respir Cell Mol Biol (1997) 1.08
Donor essential fatty acid deficiency does not prolong heterotopic cardiac allograft survival in rats. Transplantation (1991) 1.07
Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem (2005) 1.07
Serum tumor necrosis factor-alpha levels and components of the metabolic syndrome in obese adolescents. Metabolism (2004) 1.06